Do we need pharmacogenetics to personalize antidepressant therapy?

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Psychiatry

Background:

• Antidepressants are crucial for treating depressive disorders but show variable clinical responses.
• Slow onset of action, side effects, and lack of remission in a significant patient group necessitate treatment improvements.
• Individual variations in treatment outcomes are poorly understood, with genetic differences being a potential contributing factor.

Purpose of the Study:

• To review the influence of drug metabolism and drug target polymorphisms on antidepressant clinical response.
• To highlight specific polymorphisms with extensively studied effects on antidepressant therapy.
• To provide a comprehensive reference to existing literature on genetic variations and antidepressant outcomes.

Main Methods:

• Literature review focusing on polymorphisms in drug metabolizing enzymes and drug targets.
• Analysis of studies examining the clinical impact of specific genetic variations.
• Compilation of findings in a tabular format for comprehensive reference.

Main Results:

• Polymorphisms in drug metabolizing enzymes, such as cytochromes P450 2D6 (CYP2D6) and cytochrome P450 2C19 (CYP2C19), can be relatively easy to predict and may help explain or prevent adverse effects.
• The impact of drug target polymorphisms on treatment response is more challenging to establish.
• Drug target polymorphisms might be more relevant for disease susceptibility and presentation than for predicting response to antidepressant therapy.

Conclusions:

• Genetic variations, particularly in drug metabolizing enzymes, play a role in individual responses to antidepressants.
• Predicting the clinical impact of drug target polymorphisms requires further investigation.
• Understanding pharmacogenetics can potentially optimize antidepressant selection and minimize adverse events.